

Prospective study, CD on vedolizumab open label (0,2,6 and q8 thereafter). Patients with less than 70 points decrease in CDAI had extra dose in w10. Endoscopy performed at baseline, w26 and w52.

Endoscopic outcomes: endoscopic and histological remission/ response w52

Clinical outcomes: steroid free remission, clinical response, biochemical remission.

Results:

- w26 and w52, 29% and 31% steroid free remission.
- ITT analysis, endoscopic remission w26 & w52 33% and 36%
- Endoscopic response w26 and w52, 40% and 45%
- Serum levels of VDZ >10mg/L w22 associated with remission w26

Conclusions:

One-third of patients with CD achieve remission after 52w treatment of Vedolizumab. Two-thirds achieve histologic remission at w26.

Figure 1. Proportion of patients achieving steroid-free clinical remission (CDAI <150), clinical response (at least 70-point drop in CDAI compared with baseline), endoscopic remission (SES-CD <4) and endoscopic response (50% reduction in SES-CD compared with baseline) at week 26 and week 52. Proportions were determined in nonresponder imputation population (n = 110).

